Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OV101 in Fragile X Syndrome
NCT03697161Phase 2Completed
- Sponsor
- Healx
- Start
- Sep 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gaboxadol in Fragile X syndrome (FXS) (3 arms), sponsored by Healx. Primary endpoint: Treatment Emergent Adverse Events at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
gaboxadol
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03697161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697161.